BioPharma Resources

Investigational drug · Phase 3

IBI311

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease, Thyroid Eye Disease, TED.

Phase 3

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

1 still active

All registered trials

10

Any phase or sponsor naming "IBI311"

First trial start

2023

Oct 20, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "IBI311", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Thyroid Eye Disease
  • Thyroid Eye Disease, TED

Approved drugs for the same conditions: Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "IBI311" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Thyroid Eye Disease

  • VRDN-003ZL-1109Phase 35 trials

    Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)

  • BatoclimabIMVT-1401Phase 33 trials

    Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease

  • PacibekitugTOUR006, PAC001Phase 33 trials

    Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases

  • KHN939Phase 32 trials

    Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease

  • linsitinibPhase 32 trials

    Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease

  • AMG 732Phase 22 trials

    Amgen · Thyroid Eye Disease

  • LASN01Phase 22 trials

    Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy

  • lonigutamabPhase 21 trial

    ACELYRIN Inc. · Thyroid Eye Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.